Combination therapy is a rational strategy to optimize therapeutic benefits and minimize risks associated with treatment of patients with multiple sclerosis (MS). A recent study reporting negative results of combination therapy in MS should not discourage investigators from future attempts to identify optimal combinations for the treatment of this disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Prediction of combination therapies based on topological modeling of the immune signaling network in multiple sclerosis
Genome Medicine Open Access 16 July 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sorensen, P. S. et al. Simvastatin as add-on therapy to interferon beta-1a for relapsing–remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol. 10, 691–701 (2011).
Menge, T., Hartung, H. P. & Stuve, O. Statins—a cure-all for the brain? Nat. Rev. Neurosci. 6, 325–331 (2005).
Neuhaus, O. et al. Statins as immunomodulators: comparison with interferon-β1b in MS. Neurology 59, 990–997 (2002).
Youssef, S. et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, 78–84 (2002).
Cohen, J. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402–415 (2010).
Birnbaum, G., Cree, B., Altafullah, I., Zinser, M. & Reder, A. T. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 71, 1390–1395 (2008).
Rudick, R. et al. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology 72, 1989–1993 (2009).
Kieseier, B. C. & Stüve, O. A critical appraisal of treatment decisions in multiple sclerosis—old versus new. Nat. Rev. Neurol. 7, 255–262 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.C. Kieseier has received honoraria for lecturing, travel expenses for attending meetings, and financial support for research from Bayer Health Care, Biogen Idec, Merck Serono, Novartis, Roche, Sanofi Aventis, and TEVA Neuroscience.
O. Stüve has been a consultant for EMD-Serono, Genzyme, Novarits, Roche, Sanofi Aventis, and Teva Neuroscience. He has received speaker honoraria from Teva Neuroscience.
Rights and permissions
About this article
Cite this article
Kieseier, B., Stüve, O. Combination therapy in MS—still a valid strategy. Nat Rev Neurol 7, 659–660 (2011). https://doi.org/10.1038/nrneurol.2011.164
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2011.164
